Pancreatic Cancer Research

ResearcherUniversity of North Carolina at Chapel HillActive in the last 2 years

Kirsten L. Bryant

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4026-0942; OpenAlex author ID A5077659587; NIH RePORTER profile ID 12224499. Sources: OpenAlex.

Their work

Papers
21 (first author 0, last author 5)
Trials
0
Grants
3
Labs led
1
Collaborators
88
Papers, trials and grants by year

2014: 1 paper · 2015: 1 grant · 2016: 2 papers · 2017: none · 2018: none · 2019: 2 papers · 2020: 2 papers, 1 grant · 2021: 1 paper · 2022: 2 papers · 2023: 2 papers · 2024: none · 2025: 6 papers, 1 grant · 2026: 3 papers

Papers 21

  1. KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-24-1984↗
  2. CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-1835↗
  3. Vertical inhibition of the autophagy pathway impairs growth and enhances sensitivity to mTORC1 inhibition in pancreatic ductal adenocarcinoma Last author DOI 10.64898/2026.06.28.734981↗
  4. ERK signaling promotes IKKε expression and oncogenic functions in pancreatic cancer cells in association with TBK1. Co-author DOI 10.1016/j.jbc.2025.110535↗
  5. Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. Co-author DOI 10.1126/scisignal.adu7145↗
  6. Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-24-1757↗
  7. Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Ca… Co-author DOI 10.1158/0008-5472.can-25-1507↗
  8. Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreat… Co-author DOI 10.1200/po-25-00332↗
  9. Dordaviprone/ONC201 Activation of the ClpP Mitochondrial Protease Inhibits the Growth of KRAS-Mutant Pancreatic Cancer and Overcomes RAS Inhibitor Resistance Co-author DOI 10.64898/2025.12.01.691471↗
  10. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-22-0391↗
  11. VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target in KRAS-mutant pancreatic cancer. Co-author DOI 10.18632/genesandcancer.231↗
  12. Susceptibility to autophagy inhibition is enhanced by dual IGF1R and MAPK/ERK inhibition in pancreatic cancer. Last author DOI 10.1080/15548627.2022.2042782↗
  13. Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors. Last author DOI 10.1158/0008-5472.can-21-1443↗
  14. CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. Co-author DOI 10.1016/j.celrep.2021.110060↗
  15. Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Co-author DOI 10.1038/s41591-020-0947-8↗
  16. Atypical KRAS G12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-19-1006↗
  17. Blocking autophagy to starve pancreatic cancer. Co-author DOI 10.1038/s41580-019-0120-8↗
  18. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Co-author DOI 10.1038/s41591-019-0368-8↗
  19. Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. Co-author DOI 10.1016/j.ccell.2015.11.011↗
  20. KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment. Last author DOI 10.3390/cancers8040045↗
  21. KRAS: feeding pancreatic cancer proliferation. Co-author DOI 10.1016/j.tibs.2013.12.004↗

Grants 3

  1. Mechanistic dissection and inhibitor targeting of autophagy in RAS driven cancers R37CA251877↗
  2. FY20 Idea Development Award, Early-Career Investigator Option: Kirsten Bryant AWARD cdmrp_pcarp:2020-kirsten-bryant-fy20-idea-development-award-early-career
  3. Exploiting pancreatic cancer cell metabolism for therapeutic gain AWARD pancan:2015-kirsten-bryant-phd-exploiting-pancreatic-cancer-cell-metabo

Closest collaborators

The 25 strongest of 88 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Channing J. Der · 18 shared papers, 2014–2026 · strength 2.49
  2. Clint A. Stalnecker · 13 shared papers, 2019–2026 · strength 2.17
  3. Adrienne D. Cox · 13 shared papers, 2016–2026 · strength 1.76
  4. Mariaelena Pierobon · 10 shared papers, 2016–2026 · strength 1.24
  5. Kristina Drizyte‐Miller · 6 shared papers, 2021–2025 · strength 0.99
  6. Andrew M. Waters · 7 shared papers, 2019–2026 · strength 0.84
  7. Craig M. Goodwin · 6 shared papers, 2020–2026 · strength 0.82
  8. Jennifer E. Klomp · 7 shared papers, 2019–2025 · strength 0.80
  9. Jonathan M. DeLiberty · 5 shared papers, 2020–2026 · strength 0.75
  10. Emanuel F. Petricoin · 4 shared papers, 2023–2025 · strength 0.69
  11. Emanuel F. Petricoin · 7 shared papers, 2016–2025 · strength 0.68
  12. Ryan N. Robb · 3 shared papers, 2025–2026 · strength 0.64
  13. Mallory K. Roach · 3 shared papers, 2025–2026 · strength 0.64
  14. Bjoern Papke · 6 shared papers, 2019–2023 · strength 0.57
  15. A. Cole Edwards · 3 shared papers, 2022–2026 · strength 0.52
  16. J. Nathaniel Diehl · 5 shared papers, 2019–2025 · strength 0.49
  17. Andrew J. Aguirre · 3 shared papers, 2020–2026 · strength 0.45
  18. G. Aaron Hobbs · 4 shared papers, 2019–2026 · strength 0.43
  19. Sarah E. Ackermann · 2 shared papers, 2025–2026 · strength 0.40
  20. Michael F. Coleman · 2 shared papers, 2022 · strength 0.39
  21. Lee M. Graves · 2 shared papers, 2025 · strength 0.39
  22. Pankaj Kumar Singh · 3 shared papers, 2019–2026 · strength 0.36
  23. Ye S. Lee · 2 shared papers, 2021–2023 · strength 0.27
  24. Adam C. Graves · 1 shared paper, 2025 · strength 0.27
  25. ALBERT Sidney BALDWIN · 1 shared paper, 2025 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.